MNTA Momenta Pharmaceuticals Inc.
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
- 13.83 P/E
- 13.93 P/S
- 3.53 P/B
- -1.91 EPS
- -146.29% Cash ROIC
- 11.20 Cash Ratio
- 0 / 0% Dividend
- 702,838.00 Avg. Vol.
- 53.31M Shares
- 745.3M Market Cap.
Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans (HSPGs). The company applies its technology for the development of generic versions of complex drug products, as well as for th...
GlobeNewswire (press release) - 16 hours ago
Motley Fool - Feb 19, 2015
Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial ... - GlobeNewswire (press release)
Motley Fool - Nov 5, 2014
Momenta Pharmaceuticals' (MNTA) CEO Craig Wheeler on Q3 2014 Results ... - Seeking Alpha (registration)
Nasdaq - Feb 4, 2015
Momenta Pharmaceuticals Announces Date of Fourth Quarter and Year End ... - MarketWatch
Equities.com - Feb 25, 2015
Schaeffers Research (blog) - Feb 13, 2015
Equities.com - Feb 19, 2015
Ashburn Daily - Feb 22, 2015
Motley Fool - May 6, 2014
Time to Pick Up the Momenta Pharmaceuticals Pieces (RDY, TEVA, MNTA) - SmallCap Network
Ashburn Daily - Feb 25, 2015
Insider Selling: Craig A. Wheeler Sells 2110 Shares of Momenta ... - Dakota Financial News